Fol. Biol. 2010, 56, 51-57
https://doi.org/10.14712/fb2010056020051
CCAAT/Enhancer-Binding Protein α (CEBPA) Polymorphisms and Mutations in Healthy Individuals and in Patients with Peripheral Artery Disease, Ischaemic Heart Disease and Hyperlipidaemia
References
1. 2003) Translocation and gross deletion breakpoints in human inherited disease and cancer I: Nucleotide composition and recombination-associated motifs. Hum. Mutat. 22, 229-244.
< , S. S., Chuzanova, N., Krawczak, M., Ball, E. V., Cooper, D. N. (https://doi.org/10.1002/humu.10254>
2. 2003) Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate risk AML. Hematol. J. 4, 31-40.
< , S., Erpelinck, C., Meijer, J., van Oosterhoud, S., van Putten, W. L., Valk, P. J., Berna Beverloo, H., Tenen, D. G., Löwenberg, B., Delwel, R. (https://doi.org/10.1038/sj.thj.6200216>
3. 2001) Instability of repetitive DNA sequences: The role of replication in multiple mechanisms. Proc. Natl. Acad. Sci. USA 98, 8319-8325.
< , M., Lovett, S. T. (https://doi.org/10.1073/pnas.111008398>
4. 2003) Translocation and gross deletion breakpoints in human inherited disease and cancer II: Potential involvement of repetitive sequence elements in secondary structure formation between DNA ends. Hum. Mutat. 22, 245-251.
< , N., Abeysinghe, S. S., Krawczak, M., Cooper, D. N. (https://doi.org/10.1002/humu.10253>
5. 1998) The role of C/EBPα genes in adipocyte differentiation. J. Biol. Chem. 273, 30057-30060.
< , G. J., Ross, S. E., MacDougald, O. A. (https://doi.org/10.1074/jbc.273.46.30057>
6. 1992) Two alternative pathways of double-strand break repair that are kinetically separable and independently modulated. Mol. Cell. Biol. 12, 1292-1303.
, J., Rudin, N., Haber, J. S. (
7. 2007) C/EBPα induces PU.1 and interacts with AP-1 and NF-κB to regulate myeloid development. Blood Cells Mol. Dis. 39, 340-343.
< , A. D. (https://doi.org/10.1016/j.bcmd.2007.06.010>
8. 2004) CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J. Clin. Oncol. 22, 624-633.
< , S., Schlenk, R. F., Stolze, I., Bihlmayr, J., Benner, A., Kreitmeier, S., Tobis, K., Döhner, H., Döhner, K. (https://doi.org/10.1200/JCO.2004.06.060>
9. 2007) Growth-inhibiting activity of transcription factor C/EBPα, its role in haematopoiesis and its tumour suppressor or oncogenic properties in leukaemias. Folia Biol. (Praha) 53, 97-108.
, O. (
10. 2008) CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin’s lymphoma. Blood Cells Mol. Dis. 40, 401-405.
< , O., Provaznikova, D., Kocova, M., Kostecka, A., Cvekova, P., Neuwirtova, R., Kobylka, P., Cermak, J., Brezinova, J., Schwarz, J., Markova, J., Salaj, P., Klamova, H., Maaloufova, J., Lemez, P., Novakova, L., Benesova, K. (https://doi.org/10.1016/j.bcmd.2007.11.005>
11. 2002) Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein α in myelodysplastic syndromes and myeloid leukemias. Blood 99, 1332-1340.
< , A. F., Hofmann, W. K, Kawano, S., Takeuchi, S., Krug, U., Kwok, S. H., Larsen, R. J., Asou, H., Miller, C. W., Hoelzer, D., Koeffler, H. P. (https://doi.org/10.1182/blood.V99.4.1332>
12. 1992) The CCAAT/enhancer binding protein (C/EBPα) gene (CEBPA) maps to human chromosome 19q13.1 and the related nuclear factor NF-IL6 (C/EBP ß) gene (CEBPB) maps to human chromosome 20q13.1. Genomics 14, 12-17.
< , L. R., Bachinski, L. L., Sicilliano, M. J., Fertitta, A., Trask, B., de Jong, P. J., Ledbetter, D. H., Darlington, G. J. (https://doi.org/10.1016/S0888-7543(05)80276-9>
13. 2004) Disruption of hepatic C/EBPα results in impaired glucose tolerance and age-dependent hepatosteatosis. J. Biol. Chem. 279, 44740-44748.
< , Y., Inoue, J., Lambert, G., Yim, S. H., Gonzalez, F. J. (https://doi.org/10.1074/jbc.M405177200>
14. 2005) Molecular stop signs: regulation of cell cycle arrest by C/EBP transcription factors. J. Cell Sci. 118, 2545-2555.
< , P. F. (https://doi.org/10.1242/jcs.02459>
15. 2008) Identification of three loci affecting HDL-cholesterol levels in a screen for chemically induced recessive mutations in mice. J. Lipid Res. 50, 534-545.
< , T., Véniant, M. M., Helmering, J., Babij, P., Baker, D. M., Damore, M. A., Bass, M. B., Gyuris, T., Chhoa, M., Li, C. M., Ebeling, C., Amato, J., Carlson, G. A., Lloyd, D. J. (https://doi.org/10.1194/jlr.M800471-JLR200>
16. 2003) Transcription activation function of C/EBPα is required for induction of granulocytic differentiation. Blood 102, 1267-1275.
< , K., Santilli, G., Corradini, F., Perrotti, D., Calabretta, B. (https://doi.org/10.1182/blood-2003-02-0477>
17. 1991) Gene deletions causing human genetic disease: mechanisms of mutagenesis and the role of the local DNA sequence environment. Hum. Genet. 86, 425-441.
< , M., Cooper, D. N. (https://doi.org/10.1007/BF00194629>
18. 2008) What causes mitochondrial DNA deletions in human cells? Nat. Genet. 40, 275-279.
< , K. J., Reeve, A. K., Samuels, D. C., Chinnery, P. F., Blackwood, J. K., Taylor, R. W., Wanrooij, S., Spelbrink, J. N., Lightowlers, R. N., Turnbull, D. M. (https://doi.org/10.1038/ng.f.94>
19. 2008) CCAAT/enhancer binding protein-α polymorphisms occur more frequently than mutations in acute myeloid leukemia and exist across all cytogenetic risk groups and leukemia subtypes. Int. J. Cancer 123, 2321-2326.
< , A., Tocharoentanaphol, C., Auewarakul, C. U. (https://doi.org/10.1002/ijc.23796>
20. 1994) Mitochondrial DNA alterations and genetic diseases: a review. Biomed. Pharmacother. 48, 199-214.
< , P., Bataillé, N. (https://doi.org/10.1016/0753-3322(94)90134-1>
21. 2005) CEBPα mutations in childhood acute myeloid leukemia. Leukemia 19, 410-414.
< , D. C., Shih, L. Y., Huang, C. F., Hung, I. J., Yang, C. P., Liu, H. C., Jaing, T. H., Wang, L.Y., Chang, W. H. (https://doi.org/10.1038/sj.leu.2403608>
22. 2005) Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin. Cancer Res. 11, 1372-1379.
< , L. I., Chen, C. Y., Lin, D. T., Tsay, W., Tang, J. L., Yeh, Y. C., Shen, H. L., Su, F. H., Yao, M., Huang, S. Y., Tien, H. F. (https://doi.org/10.1158/1078-0432.CCR-04-1816>
23. 2006) C/EBPα is required for lung maturation at birth. Development 133, 1155-1164.
< , P. C., Whitsett, J. A., Xu, Y., Perl, A. K. T., Wan, H., Ikegami, M. (https://doi.org/10.1242/dev.02273>
24. 2001) McBindall – a better name for CCAAT/enhancer binding proteins? Cell 107, 259-261.
< , S. L. (https://doi.org/10.1016/S0092-8674(01)00543-8>
25. 2004) The CCAAT enhancer-binding protein α (C/EBPα) requires a SWI/SNF complex for proliferation arrest. J. Biol. Chem. 279, 7353-7358.
< , C., Calkhoven, C. F., Sha, X., Leutz, A. (https://doi.org/10.1074/jbc.M312709200>
26. 2004) C/EBPα mutations in acute myeloid leukaemias. Nat. Rev. Cancer 4, 394-400.
< , C. (https://doi.org/10.1038/nrc1363>
27. 2008) CCAAT/enhancer binding protein α (C/EBPα) in adipose tissue regulates genes in lipid and glucose metabolism and a genetic variation in C/EBPα is associated with serum levels of triglycerides. J. Clin. Endocrinol. Metab. 93, 4880-4886.
< , L. E., Orho-Melander, M., William-Olsson, L., Sjöholm, K., Sjöström, L., Groop, L., Carlsson, B., Carlsson, L. M., Olsson, B. (https://doi.org/10.1210/jc.2008-0574>
28. 2001) Dominant negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα) in acute myeloid leukemia. Nat. Genet. 27, 263-270.
< , T., Mueller, B. U., Zhang, P., Radomska, H. S., Narravula, S., Schnittger, S., Behre, G., Hiddermann, W., Tenen, D. G. (https://doi.org/10.1038/85820>
29. 2009) Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br. J. Cancer 100, 1343-1346.
< , T., Eyholzer, M., Fos, J., Mueller, B. U. (https://doi.org/10.1038/sj.bjc.6604977>
30. 2001) Cooperation between C/EBPα, TBP/TFIIB and SWI/SNF recruiting domains is required for adipocyte differentiation. Genes Dev. 15, 3208-3216.
< , T. A., Kowenz-Leutz, E., Leutz, A., Nerlov, C. (https://doi.org/10.1101/gad.209901>
31. 2001) E2F repression by C/EBPα is required for adipogenesis and granulopoiesis in vivo. Cell 107, 247-258.
< , B. T., Pedersen, T. A., Xu, X., Lindberg, B., Wewer, U. M., Friis-Hansen, L., Nerlov, C. (https://doi.org/10.1016/S0092-8674(01)00516-5>
32. 2006) The proline-histidine rich CDK2/CDK4 interaction region of C/EBPα is dispensable for C/EBPα-mediated growth regulation in vivo. Mol. Cell. Biol. 26, 1028-1037.
< , B. T., Pedersen, T. A., Hasemann, M. S., Schuster, M. B., Kirstetter, P., Luedde, T., Damgaard, I., Kurz, E., Schjerling, C. K., Nerlov, C. (https://doi.org/10.1128/MCB.26.3.1028-1037.2006>
33. 2007) Genetic changes of CEBPA in cancer: mutations or polymorphism? J. Clin. Oncol. 25, 2493-2494.
< , C., Regalo, G., Durães, C., Carneiro, F., Machado, J. C. (https://doi.org/10.1200/JCO.2007.10.7227>
34. 2004) Two direct repeats cause most human mtDNA deletions. Trends Genet. 20, 393-398.
< , D. C., Schon, E. A., Chinnery, P. F. (https://doi.org/10.1016/j.tig.2004.07.003>
35. 2006) C/EBPα: a tumour suppressor in multiple tissues? Biochim. Biophys. Acta 1766, 88-103.
, M. B., Porse, B. T. (
36. 2004) A dominant-negative mutant of C/EBPα, associated with acute myeloid leukemias, inhibits differentiation of myeloid and erythroid progenitors of man but not mouse. Blood 103, 2744-2752.
< , M., Löhler, J., Fischer, M., Herwig, U., Tenen, D. G., Stocking, C. (https://doi.org/10.1182/blood-2003-07-2280>
37. 1983) The double-strand-break repair model for recombination. Cell 33, 25-35.
< , J. W., Orr-Weaver, R. J., Rothstein, R. J., Stahl, F. W. (https://doi.org/10.1016/0092-8674(83)90331-8>
38. 1992) A mechanism for deletion formation in DNA by human cell extracts: the involvement of short sequence repeats. Nucleic Acids Res. 20, 6183-6188.
< , J., Chalk, J., Ganesh, A., North, P. (https://doi.org/10.1093/nar/20.23.6183>
39. 1996) CCAAT/enhancer-binding protein α (C/EBPα) inhibits cell proliferation through the p21 (WAF-1/CIP-1/SDI-1) protein. Genes Dev. 10, 804-815.
< , N. A., Wilde, M., Nakanishi, M., Smith, J. R., Darlington, G. J. (https://doi.org/10.1101/gad.10.7.804>
40. 1997) CCAAT/enhancer-binding protein α regulates p21 protein and hepatocyte proliferation in newborn mice. Mol. Cell. Biol. 17, 7353-7361.
< , N. A., Harris, T. E., Wilde, M., Bilyeu, T. A., Burgess-Beusse, B .L., Finegold, M. J., Darlington, G. J. (https://doi.org/10.1128/MCB.17.12.7353>
41. 2004) Prognostically useful gene expression profiles in acute myeloid leukemia. N. Engl. J. Med. 350, 1617-1628.
< , P. J., Verhaak, R. G., Beijen, M. A., Erpelinck, C. A., Barjesteh van Waalwijk van Doorn-Khosrovani, S., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., Delwel, R. (https://doi.org/10.1056/NEJMoa040465>
42. 2001) C/EBPα arrests cell proliferation through direct inhibition of Cdk2 and Cdk4. Mol. Cell 8, 817-828.
< , H., Iakova, P., Wilde, M., Welm, A., Goode, T., Roesler, W. J., Timchenko, N. A. (https://doi.org/10.1016/S1097-2765(01)00366-5>
43. 2002) C/EBPα triggers proteasome-dependent degradation of cdk4 during growth arrest. EMBO J. 21, 930-941.
< , H., Goode, T., Iakova, P., Albrecht, J. H., Timchenko, N.A. (https://doi.org/10.1093/emboj/21.5.930>
44. 2007) A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering of AML. Blood 109, 389-390.
< , B. J., Louwers, I., Valk, P. J., Löwenberg, B., Delwel, R. (https://doi.org/10.1182/blood-2006-08-042325>
45. 2009) Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 113, 3088-3091.
< , B. J., Löwenberg, B., Erpelinck-Verschueren, C. A. J., van Putten, W. L., Valk, P. J., Delwel, R. (https://doi.org/10.1182/blood-2008-09-179895>